Recon: Pfizer seeks authorization for bivalent booster in kids under 5; FDA takes firmer stance on dangling accelerated approvals
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy